[1] 世界卫生组织. 2017年世界艾滋病日:人人都重要[EB/OL]. [2017-12-01]. http://www.who.int/campaigns/aids-day/2017/zh/.
[2] Dieffenbach CW,Fauci AS.Thirty years of HIV and AIDS:future challenges and opportunities[J]. Ann Intern Med, 2011, 154(11):766-771.
[3] 孔德生, 马丽英. HIV的清除和艾滋病功能性治愈[J]. 中国热带医学,2016,16(11): 1145-1150.
[4] Lorenzo-Redondo R, Fryer HR, Bedford T, et al.Persistent HIV-1 replication maintains the tissue reservoir during therapy[J]. Nature, 2016, 530(7588): 51-56.
[5] Bullen CK, Laird GM, Durand CM, et al.New ex vivo approaches distinguisheffectiveand ineffective single agents for reversing HIV-1latency in vivo[J]. Nat Med, 2014, 20(4):425-429.
[6] Spivak AM, Bosque A, Balch AH,et al.Ex Vivo Bioactivity and HIV 1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in RestingCD4(+) T Cells from Aviremic Patients[J]. Antimicrob Agents Chemother, 2015, 59(10): 5984-5991.
[7] Xing S, Siliciano RF.Targeting HIV latency: pharmacologic strategies toward eradication[J]. Drug Discov Today, 2013 , 18(11-12): 541-551.
[8] Pache L, Dutra MS, Spivak AM, et al.BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency[J]. Cell Host Microbe, 2015, 18(3): 345-353.
[9] Li P, Kaiser P, Lampiris HW, et al.Stimulating the RIG-I pathway to kill cellsinthe latent HIV reservoir followingviral reactivation[J]. Nat Med, 2016, 22(7): 807-811.
[10] Lim SY, Osuna CE, Hraber PT, et al.TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy[J]. Sci Transl Med, 2018, 10(439): e4521.
[11] Garces F, Sok D, Kong L, et al.Structural evolution of glycan recognition by a family of potent HIV antibodies[J]. Cell, 2014, 159(1):69-79.
[12] Borducchi EN, Cabral C, Stephenson KE.et al.Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys[J]. Nature, 2016, 540(7632): 284-287.
[13] Baden eLR, Walsh SR, Saman MS,et al. First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector[J]. J Infect Dis, 2018 , 218(4):55-59.
[14] Wu X, Guo J, Niu M, et al.Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice[J]. J Clin Invest, 2018, 128(6): 2239-2251.
[15] Huang J, Kang BH, Pancera M,et al.Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120interface[J]. Nature, 2014, 515(7525): 138-142.
[16] Byrareddy SN, Arthos J, Cicala C.Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy[J]. Science, 2016, 354(6309): 197-202.
[17] Dan Barouch. PGT121 COMBINED WITH GS-9620 DELAYS VIRAL REBOUND IN SHIV-INFECTED RHESUS MONKEYS. CROI 2018.Boston[EB/OL]. [2018-106-30]. http://www.croiwebcasts.org/portal.
[18] Hütter G.More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation[J]. N Engl J Med, 2014, 371(25): 2437-2438.
[19] An DS,Donahue RE, Kamata M, et al.Stablereduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates[J]. Proc Natl Acad Sci U S A. 2007, 104(32): 13110-13115.
[20] Shimizu S, Ringpis GE, Marsden MD, et al.RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice[J]. Mol Ther Nucleic Acids, 2015, 4: e227.
[21] Choi JG, Bharaj P, et al.Abraham S.Multiplexing sevenmiRNA- BasedshRNAsto suppress HIV replication[J]. Mol Ther, 2015, 23(2): 310-320.
[22] Soriano V.Hot News: Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure[J]. AIDS Rev, 2017, 19(3): 167-172.
[23] Yin C, Zhang T, Qu X, et al.In VivoExcision of HIV-1 Provirusby saCas9and Multiplex Single-Guide RNAs in Animal Models[J]. Mol Ther, 2017, 25(5): 1168-1186.
[24] 康文,孙永涛. HIV脑内储存库——功能性治愈的另一障碍[J]. 传染病信息,2016, 29(6): 324-327.
[25] Shiau S, Kuhn L.Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby[J]. Expert Rev Anti Infect Ther, 2014 , 12(3): 307-318. |
